Predictive Biomarkers for Drugs Targeting ALK/p53 in Neuroblastoma

• Research type

  Research Study

• Full title

  Pilot Study to Develop Predictive Biomarkers for Drugs Targeting the ALK and p53 Pathways for Children with Neuroblastoma

• IRAS ID

  126061

• Contact name

  Andrew DJ Pearson

• Contact email

  andrew.pearson@icr.ac.uk

• Sponsor organisation

  The Royal Marsden NHS Foundation Trust

• Research summary

  The aim of this study is to collect tissue samples (blood, tumour and bone marrow) from children with neuroblastoma to develop techniques to identify new mutations (particularly in ALK and TP53 genes) in circulating free tumour DNA in the blood. This strategy avoids invasive approaches such as direct tumour biopsy. In the future, identification of the genomic aberrations will greatly facilitate personalised medicine for children with neuroblastoma with each receiving therapy according to their own tumour’s molecular profile.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  13/LO/1459

• Date of REC Opinion

  24 Dec 2013

• REC opinion

  Further Information Favourable Opinion